AMAG Pharmaceuticals, Inc. Expected to Earn FY2022 Earnings of $1.78 Per Share (AMAG)

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) – Equities research analysts at B. Riley issued their FY2022 EPS estimates for shares of AMAG Pharmaceuticals in a report released on Tuesday. B. Riley analyst D. Buck forecasts that the specialty pharmaceutical company will post earnings of $1.78 per share for the year. B. Riley currently has a “Hold” rating and a $16.00 target price on the stock.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.57 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $1.61. AMAG Pharmaceuticals had a negative net margin of 35.35% and a negative return on equity of 0.64%.

A number of other research analysts also recently issued reports on AMAG. Piper Jaffray Companies restated a “hold” rating and issued a $15.00 price target on shares of AMAG Pharmaceuticals in a research report on Thursday. Cantor Fitzgerald reiterated a “hold” rating and issued a $21.00 price objective on shares of AMAG Pharmaceuticals in a research report on Thursday, September 28th. Janney Montgomery Scott reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Tuesday, October 17th. Morgan Stanley cut their price objective on shares of AMAG Pharmaceuticals from $26.00 to $22.00 and set an “overweight” rating on the stock in a research report on Friday, November 3rd. Finally, Zacks Investment Research upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price objective on the stock in a research report on Wednesday, October 4th. Twelve analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. AMAG Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $21.00.

AMAG Pharmaceuticals (NASDAQ AMAG) traded up $0.60 during trading on Wednesday, hitting $13.85. 611,747 shares of the stock were exchanged, compared to its average volume of 808,954. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.59. AMAG Pharmaceuticals has a one year low of $11.93 and a one year high of $25.20. The company has a market cap of $488.74, a P/E ratio of -2.28 and a beta of 0.79.

A number of large investors have recently modified their holdings of the stock. State Street Corp lifted its position in AMAG Pharmaceuticals by 10.6% in the 2nd quarter. State Street Corp now owns 2,789,932 shares of the specialty pharmaceutical company’s stock valued at $51,336,000 after purchasing an additional 267,873 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of AMAG Pharmaceuticals by 18.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,215,249 shares of the specialty pharmaceutical company’s stock worth $22,361,000 after buying an additional 189,576 shares in the last quarter. Gotham Asset Management LLC raised its position in shares of AMAG Pharmaceuticals by 17.8% during the 2nd quarter. Gotham Asset Management LLC now owns 800,055 shares of the specialty pharmaceutical company’s stock worth $14,721,000 after buying an additional 121,137 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of AMAG Pharmaceuticals by 1.7% during the 2nd quarter. Renaissance Technologies LLC now owns 778,800 shares of the specialty pharmaceutical company’s stock worth $14,330,000 after buying an additional 12,800 shares in the last quarter. Finally, Prudential Financial Inc. raised its position in shares of AMAG Pharmaceuticals by 35.7% during the 3rd quarter. Prudential Financial Inc. now owns 725,357 shares of the specialty pharmaceutical company’s stock worth $13,382,000 after buying an additional 190,660 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: This news story was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://ledgergazette.com/2018/01/19/amag-pharmaceuticals-inc-expected-to-earn-fy2022-earnings-of-1-78-per-share-amag.html.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Earnings History and Estimates for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply